Interesting ANN. The research conducted by Weill seems to identify, perhaps by luck or other, that the active ingredient in Veyonda is key in the abscopal response.
Best parts of the ANN, which I find the most interesting 'The relevance of this to Noxopharm is that blocking autophagy is one of the recognised anti-cancer mechanisms used by idronoxil, the active ingredient in Veyonda.' & 'The Weill Cornell discovery, combined with what we learnt from the DARRT-1 study about Veyonda dosing, means we go into the upcoming DARRT-2 study with a high degree of confidence that we are on the edge of a major breakthrough in cancer therapy'
NOX Price at posting:
62.0¢ Sentiment: Buy Disclosure: Held
